Pharmacist Collaborative Practice Agreements: Who, What, Why, and How

In 2015, cardiovascular disease alone contributed to one in three deaths. Interventions to reduce the incidence and prevalence of hypertension and other risk factors for cardiovascular disease can focus on removing existing barriers to efficient care delivery. A team-based, patient-centered approach to care results in personalized, timely, and empowered patient care as well as facilitates communication and coordination among team members.

Pharmacists are well positioned to assist the healthcare team in the treatment and management of chronic disease due to their expert knowledge and training in medication management as well as their high accessibility to the public. This session will provide an overview of the impact of chronic disease and the opportunity for pharmacists to improve patient outcomes, define and explain collaborative practice agreements and the variations in state authority, provide helpful tips for getting started with a CPA, walk through sample language that can be used when developing an agreement, provide information on practical considerations, and finally identify further resources available in the market today.

Learning Objectives

At the completion of this application-based activity, participants will be able to:

1. Define collaborative practice agreements and identify their role in providing team-based care.
2. Describe when and how to use CPAs in the outpatient setting.
3. Consider approaches for developing a trusting relationship with another healthcare professional that may lead to the development of a CPA.
4. Identify resources available for pharmacists looking to establish a CPA.

Activity type: Knowledge-based

Target Audience: Pharmacists 

Learning Level: 2

Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following activity is approved for 1.5 contact hours of CPE credit (0.15 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-18-249-H04-P.

To obtain credit for completing Pharmacist Collaborative Practice Agreements: Who, What, Why, and How, participate in the activity, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript. 

Initial release date: October 1, 2018
Expiration date: October 1, 2021 

Development

Pharmacist Collaborative Practice Agreements: Who, What, Why, and How is a home study continuing education activity for pharmacists developed by ChangeLab Solutions and the American Pharmacists Association.

Support

This activity is supported by the Centers for Disease Control and Prevention.

Course Planners

Jeffrey M. Durthaler, M.S., R.Ph. Population Health Consultant Pharmacist, IHRC, Inc., Atlanta, GA

Erika Fulmer, MHA, Policy Analyst, Centers for Disease Control and Prevention, Atlanta, GA

Siobhan Gilchrist, JD, MPH, Health Policy Analyst, IHRC, Inc., Atlanta, GA

Christopher D. Jones, PhD, MSW, Lead Health Scientist, Centers for Disease Control and Prevention, Atlanta, GA

Rebecca Johnson, MPH, Senior Policy Analyst, ChangeLab Solutions, Oakland, CA

Lindsay Kunkle, PharmD, Senior Director, Practice Advancement & Pharmacist Engagement, ‎American Pharmacists Association, Washington, DC

Krystalyn K. Weaver, PharmD, Vice President, Policy and Operations, National Alliance of State Pharmacy Associations, Richmond, VA

Disclosures

All speakers and contributors declare no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria.

APhA’s editorial staff declares no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures. 

Conflicts of interest have been resolved through content review by Helen Sairany, PharmD, BCACP, MBA, Associate Director of Content Development at the American Pharmacists Association. 

Fee

There is no fee associated with this learning activity.

System Requirements

Computer and internet access are required to complete this activity.  Please visit our website to view the Technology System Requirements in order to have a positive learning experience.